These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25667277)

  • 1. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.
    Solomon B
    J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
    Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
    Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 8. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
    Ou SH; Bazhenova L; Camidge DR; Solomon BJ; Herman J; Kain T; Bang YJ; Kwak EL; Shaw AT; Salgia R; Maki RG; Clark JW; Wilner KD; Iafrate AJ
    J Thorac Oncol; 2010 Dec; 5(12):2044-6. PubMed ID: 21102269
    [No Abstract]   [Full Text] [Related]  

  • 10. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.
    Zhong E; Huang H
    BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS1--targeting the one percent in lung cancer.
    Gold KA
    N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.
    Killock D
    Nat Rev Clin Oncol; 2014 Nov; 11(11):624. PubMed ID: 25311353
    [No Abstract]   [Full Text] [Related]  

  • 13. [ROS-1 rearranged bronchopulmonary adenocarcinoma revealed by a pulmonary miliary].
    Brindel A; Huet D; Vaillant P; Vignaud JM; Tiotiu A
    Bull Cancer; 2018 Jun; 105(6):549-551. PubMed ID: 29706357
    [No Abstract]   [Full Text] [Related]  

  • 14. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
    Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
    Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
    [No Abstract]   [Full Text] [Related]  

  • 15. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.
    Jänne PA; Meyerson M
    J Clin Oncol; 2012 Mar; 30(8):878-9. PubMed ID: 22215755
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
    Gibelin C; Avrillon V; De La Fouchardiere A; Mc Leer-Florin A; Lantuejoul S; Fayette J
    Lung Cancer; 2016 Dec; 102():42-43. PubMed ID: 27987587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.
    Li H; Pan Y; Wang R; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):185-7. PubMed ID: 25230898
    [No Abstract]   [Full Text] [Related]  

  • 18. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Awad MM; Engelman JA; Shaw AT
    N Engl J Med; 2013 Sep; 369(12):1173. PubMed ID: 24047072
    [No Abstract]   [Full Text] [Related]  

  • 20. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.